Obesity is related to more than 200 different comorbidities
Novo Nordisk, the Danish pharmaceutical company that reshaped how the world thinks about weight loss, is now asking a deeper question: what else might these drugs heal? From the joints of osteoarthritis patients to the clouded minds of those with Alzheimer's, the company is methodically testing whether semaglutide can address the vast web of conditions that obesity weaves through human health. The answer, arriving in stages over the coming months and years, may determine not only Novo's commercial future but the boundaries of what a single molecule can do for human suffering.
- Novo Nordisk has identified over 200 obesity-linked conditions and is launching clinical trials to test whether its drugs can treat them — a strategic leap that reframes Wegovy as something far more than a weight-loss pill.
- The most consequential and uncertain bet is an Alzheimer's trial due to report results by year-end, where analysts put the odds of success at just 10% — yet a win could unlock $15 billion in annual revenue.
- The company is simultaneously absorbing the shock of 9,000 job cuts and pipeline restructuring, racing to stay ahead of Eli Lilly's aggressive push into the same competitive weight-loss market.
- Novo is narrowing its focus to higher-probability clinical bets while keeping one eye on a transformative long shot — a dual posture that reflects both discipline and desperation in equal measure.
Novo Nordisk is wagering that its blockbuster weight-loss drugs can do far more than shrink waistlines. The Danish pharmaceutical giant has mapped over 200 health conditions linked to obesity and is building a clinical program to test whether semaglutide — the active ingredient in Wegovy and Ozempic — can treat them, starting with knee osteoarthritis and sleep apnea. The company's R&D chief, Martin Holst Lange, laid out this strategy at a diabetes conference in Vienna, noting that semaglutide already carries regulatory approval for reducing cardiovascular risk, and that the company intends to move methodically through other conditions using both existing drugs and experimental candidates.
The trial drawing the most attention concerns Alzheimer's disease. Novo expects results by year-end on whether semaglutide can slow cognitive decline — a domain where treatment options remain desperately scarce. Lange called any positive signal clinically meaningful, while acknowledging the company sees it as a long shot. Wall Street agrees: UBS puts the probability of success at just 10%. But the upside is staggering — Barclays analysts estimate a successful result could generate $15 billion in additional annual revenue and establish an entirely new growth pillar for the company.
This reach for transformation is unfolding under considerable strain. Novo has announced plans to cut roughly 9,000 jobs — about 10% of its workforce — saving an estimated $1.25 billion per year while terminating some early-stage research programs. The restructuring reflects the pressure of intensifying competition from Eli Lilly, which has emerged as a serious rival in the weight-loss drug market. Novo is simultaneously tightening its focus and swinging for a historic win — and the Alzheimer's results, arriving within months, will offer the first real signal of whether that combination of discipline and ambition can hold.
Novo Nordisk is placing a bet that stretches far beyond weight loss. The Danish pharmaceutical giant plans to test whether its blockbuster drugs—Wegovy chief among them—can treat a constellation of conditions that shadow obesity: knee osteoarthritis, sleep apnea, and potentially dozens more. The company has identified over 200 health conditions linked to excess weight, and it intends to build clinical evidence that its medications can address them.
Martin Holst Lange, who leads research and development at Novo Nordisk, outlined this expansion strategy during an interview at the European Association for the Study of Diabetes conference in Vienna. The company has already secured regulatory approval for semaglutide—the active ingredient in both Wegovy and Ozempic—as a treatment to reduce the risk of major cardiovascular events like heart attacks and strokes. Now it wants to move methodically through other conditions that burden patients daily, testing both established drugs and experimental candidates like CagriSema and amycretin.
The most closely watched trial, however, concerns Alzheimer's disease. Novo expects results by year-end from a study examining whether semaglutide can slow cognitive decline in patients with the neurodegenerative condition. Lange acknowledged the stakes and the uncertainty. "Any significant results would be clinically relevant because that would imply a delay in the decline of cognitive function," he said. "In the space where very few treatments are available for patients with Alzheimer's disease, that would be meaningful." But he was candid about the risk: the company views this trial as a long shot.
Wall Street analysts have quantified that skepticism. UBS estimates just a 10 percent chance the trial succeeds. Yet if it does, the payoff would be enormous—potentially $15 billion in additional annual revenue for Novo Nordisk. Barclays analysts have flagged the Alzheimer's results as critical to whether the company can build a new pillar of sustained growth beyond its current dominance in weight-loss and diabetes treatment.
This expansion comes at a moment of strategic pressure. Novo Nordisk announced plans to cut 9,000 jobs—roughly 10 percent of its workforce—as it attempts to reignite growth and fend off competition from U.S. rival Eli Lilly, which has emerged as a formidable challenger in the weight-loss drug market. The restructuring is expected to save approximately $1.25 billion annually and includes the termination of some early-stage research programs. The company is essentially narrowing its focus to higher-probability bets while simultaneously reaching for a transformative win in Alzheimer's. The Alzheimer's trial results, due within months, will signal whether that gamble has any chance of paying off.
Notable Quotes
Any significant results would be clinically relevant because that would imply a delay in the decline of cognitive function. In the space where very few treatments are available for patients with Alzheimer's disease, that would be meaningful.— Martin Holst Lange, head of research and development at Novo Nordisk
We see this as high risk.— Martin Holst Lange, on the Alzheimer's trial
The Hearth Conversation Another angle on the story
Why is Novo Nordisk suddenly interested in osteoarthritis and sleep apnea? These seem like a departure from what made them famous.
Not really a departure—more like following the science. Obesity doesn't just make you heavier. It stresses your joints, disrupts your breathing, inflames your system. If a drug helps people lose weight, the question becomes: what else improves as a side effect? They're trying to prove it systematically.
But they're also testing Alzheimer's. That has nothing to do with weight.
That's the real gamble. Semaglutide seems to have effects on the brain beyond metabolism. If it slows cognitive decline, that's a completely different market—and a much bigger one, because Alzheimer's drugs are desperately needed. But they're being honest about the odds. They think it's unlikely to work.
So why pursue it at all if the probability is so low?
Because the upside is $15 billion a year. When you're facing competition from Eli Lilly and your growth is stalling, you can't just keep doing what you've always done. You have to swing for the fences on something. The Alzheimer's trial is that swing.
And if it fails?
They've already cut 9,000 jobs to prepare for that possibility. They're building a leaner company that can survive on their core business while waiting to see if the long shot comes in.